Jelena Osmanovic Barilar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jelena Osmanovic Barilar has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Ana Babic Perhoc
Department of Pharmacology, University of Zagreb School of Medicine, Zagreb, Croatia
25 shared publications - Ana Knezovic
Laboratory of Molecular Neuropharmacology, Department of Pharmacology and Croatian Institute of Brain Research University of Zagreb School of Medicine Zagreb Croatia
25 shared publications - Melita Salkovic-Petrisic
Department of Pharmacology, University of Zagreb School of Medicine, Zagreb, Croatia
25 shared publications - Jan Homolak
Department of Pharmacology, University of Zagreb School of Medicine, Zagreb, Croatia
21 shared publications - Davor Virag
Department of Pharmacology, University of Zagreb School of Medicine, Zagreb, Croatia
17 shared publications - Ivan Kodvanj
University of Zagreb School of Medicine
5 shared publications
Latest Publications
- Open Access
Ethical Considerations of Mitigating Data Loss: VLADISLAV, a Manifesto for Reliable Home Cage Systems
Home cage monitoring (HCM) captures longitudinal animal behavioural data without human intervention. However, the systems’ complexity is rarely addressed in their design, increasing the risk of data loss, which wastes workhours, resources, and animal lives. To assess the feasibility of implementing modern, robust architectures in complex operant HCM paradigms, the V ersati L e A utonomous D ev I ce for S cheduled L earning A ssessment V ia Wi-Fi (VLADISLAV) was developed and employed to test cognitive deficits in the intracerebroventricular streptozotocin-induced rat model of sporadic Alzheimer’s disease (sAD). Reliability was modelled against a system architecture common in commercial HCM systems by modelling the failure rate of the devices’ critical components across typical durations of animal experiments. VLADISLAV assessed multiple cognitive dimensions of a rat model of sAD with automated, scheduled testing. Its design enabled simultaneous, redundant recording to multiple devices in real time, as well as batch remote control and supervision of tens of VLADISLAVs. VLADISLAV is estimated to reduce component failure rate ∼200-fold at €40/device. Data loss due to system failure shouldn’t be accepted as a normal occurrence and robust system design is an ethical imperative. VLADISLAV’s robustness and utility demonstrate the potential of embedded networked systems, used in other industries and consumer electronics for over a decade. Today, the open source ecosystem enables cost-effective implementation of such architectures in HCM by biomedical researchers with no electronic engineering education, preventing data loss and facilitating researchers’ and technicians’ day-to-day work. Considering these findings, it is apparent that the implementation of modern architectures in HCM is long overdue.
Open AccessEthical Considerations of Mitigating Data Loss: VLADISLAV, a Manifesto for Reliable Home Cage Systems
Home cage monitoring (HCM) captures longitudinal animal behavioural data without human intervention. However, the systems’ complexity is rarely addressed in their design, increasing the risk of data loss, which wastes workhours, resources, and animal lives. To assess the feasibility of implementing modern, robust architectures in complex operant HCM paradigms, the V ersati L e A utonomous D ev I ce for S cheduled L earning A ssessment V ia Wi-Fi (VLADISLAV) was developed and employed to test cognitive deficits in the intracerebroventricular streptozotocin-induced rat model of sporadic Alzheimer’s disease (sAD). Reliability was modelled against a system architecture common in commercial HCM systems by modelling the failure rate of the devices’ critical components across typical durations of animal experiments. VLADISLAV assessed multiple cognitive dimensions of a rat model of sAD with automated, scheduled testing. Its design enabled simultaneous, redundant recording to multiple devices in real time, as well as batch remote control and supervision of tens of VLADISLAVs. VLADISLAV is estimated to reduce component failure rate ∼200-fold at €40/device. Data loss due to system failure shouldn’t be accepted as a normal occurrence and robust system design is an ethical imperative. VLADISLAV’s robustness and utility demonstrate the potential of embedded networked systems, used in other industries and consumer electronics for over a decade. Today, the open source ecosystem enables cost-effective implementation of such architectures in HCM by biomedical researchers with no electronic engineering education, preventing data loss and facilitating researchers’ and technicians’ day-to-day work. Considering these findings, it is apparent that the implementation of modern architectures in HCM is long overdue.
- Open Access
- 29 November 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (2) , 351-353
Spotlight commentary—Insulin therapy: Future directions
- 29 November 2025
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (2) , 351-353
Open AccessSpotlight commentary—Insulin therapy: Future directions
- Open Access
- 14 October 2025
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 132 (10) , 1459
Correction: New trends in the research of psychiatric and neurodegenerative diseases: a tribute to Melita Salkovic-Petrisic
- 14 October 2025
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 132 (10) , 1459
Open AccessCorrection: New trends in the research of psychiatric and neurodegenerative diseases: a tribute to Melita Salkovic-Petrisic
- Open Access
- 8 September 2025
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 132 (10) , 1457-1458
New trends in the research of psychiatric and neurodegenerative diseases: a tribute to Melita Salkovic-Petrisic
- 8 September 2025
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 132 (10) , 1457-1458
Open AccessNew trends in the research of psychiatric and neurodegenerative diseases: a tribute to Melita Salkovic-Petrisic
- 4 December 2024
- Published by Elsevier in Neuropharmacology
- Vol. 265, 110246
Modeling of Parkinson's disease by intrastriatal administration of streptozotocin
- 4 December 2024
- Published by Elsevier in Neuropharmacology
- Vol. 265, 110246
Modeling of Parkinson's disease by intrastriatal administration of streptozotocin
- Open Access
My friend MIROSLAV: A Hackable Open-Source Hardware and Software Platform for High-Throughput Rodent Activity Monitoring in the Home Cage
While conventional behavioural tests offer valuable insight into rodent behaviour in specific paradigms, rodents spend most of their time in a safe, undisturbed environment – their home cage. However, home cage monitoring (HCM) is often impractical at scale over prolonged periods of time without significant loss of data. To achieve this, we developed MIROSLAV, the Multicage InfraRed Open Source Locomotor Activity eValuator, a home cage activity and environmental monitoring device designed to be open, adaptable, and robust. Its transparent and modular design allows the device to be tailored to varying experimental requirements and environmental conditions, while its wireless operation and multiple redundancies minimise loss of data and animal disturbance. Data quality is maintained by a modular software workflow for data preparation (Prepare-a-SLAV) and cleaning (TidySLAV), followed by exploratory (MIROSine – MIRO The Explorer) and statistical (MIROSine – StatistiSLAV) analysis of circadian periodicity. Here, using MIROSLAV, we demonstrate circadian dysrhythmia and a disrupted response to regular stimuli (e.g. behavioural testing, bedding change) in a rat model of sporadic Alzheimer’s disease, showcasing MIROSLAV’s utility in a typical animal study of disease. In accordance with the 3Rs, every rodent study and laboratory performing them can benefit from HCM, provided the existence of transparent and customisable tools which allow robust deployment to tens or hundreds of cages in various conditions. MIROSLAV provides this opportunity to researchers in a cost-effective manner.
Open AccessMy friend MIROSLAV: A Hackable Open-Source Hardware and Software Platform for High-Throughput Rodent Activity Monitoring in the Home Cage
While conventional behavioural tests offer valuable insight into rodent behaviour in specific paradigms, rodents spend most of their time in a safe, undisturbed environment – their home cage. However, home cage monitoring (HCM) is often impractical at scale over prolonged periods of time without significant loss of data. To achieve this, we developed MIROSLAV, the Multicage InfraRed Open Source Locomotor Activity eValuator, a home cage activity and environmental monitoring device designed to be open, adaptable, and robust. Its transparent and modular design allows the device to be tailored to varying experimental requirements and environmental conditions, while its wireless operation and multiple redundancies minimise loss of data and animal disturbance. Data quality is maintained by a modular software workflow for data preparation (Prepare-a-SLAV) and cleaning (TidySLAV), followed by exploratory (MIROSine – MIRO The Explorer) and statistical (MIROSine – StatistiSLAV) analysis of circadian periodicity. Here, using MIROSLAV, we demonstrate circadian dysrhythmia and a disrupted response to regular stimuli (e.g. behavioural testing, bedding change) in a rat model of sporadic Alzheimer’s disease, showcasing MIROSLAV’s utility in a typical animal study of disease. In accordance with the 3Rs, every rodent study and laboratory performing them can benefit from HCM, provided the existence of transparent and customisable tools which allow robust deployment to tens or hundreds of cages in various conditions. MIROSLAV provides this opportunity to researchers in a cost-effective manner.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
The involvement of GLP1 signaling with the effect of oral galactose in the hypothalamus of sporadic Alzheimer’s disease rat model
Background: Intracerebroventricular (icv) application of streptozotocin (STZ) causes mytochondrial dysfunction, oxidative stress and other metabolic effects, which leads to accumulation of τ‐protein and Aß plaques that makes it suitable for animal model of sporadic Alzheimer’s disease (sAD). We aimed to explore whether acute effect of single oral galactose dose is mediated by glucagon‐like peptide‐1 (GLP‐1) in sAD rat model.Method: Wistar rats were injected icv with STZ (3 mg/kg) or vehicle only (CTR). One month after the injection, animals were divided into three experiments. First experiment: 200 mg/kg galactose was given orally and CTR animals were sacrificed 30, 60 and 120 min after administration. Second experiment: GLP‐1R antagonist (Exendin 9‐39, 85 µg/kg; GLP1Ra) was administered icv in both groups and animals were sacrificed 30 min after the injection. Third experiment: 30 min prior to oral galactose, rats were injected icv with GLP‐1Ra, and animals were sacrificed 120 min after galactose load. PDH, COXIV, CytC and Casp‐3 levels were measured by Western blot method and lactate, ATP and SOD were measured by ELISA in HPT. Glucose, galactose and GLP‐1 levels were measured in plasma and CSF. Data were analyzed by principal component analysis and Spearman rank correlation.Result: Metabolic changes were found more pronounced 120 min after single galactose load: reduced levels of Casp‐3 and PDH and increased SOD levels in HPT; increased CSF glucose. GLP1Ra decreased the levels of lactate, COXIV and CytC and increased PDH and Casp‐3 levels in HPT, only in STZ treated animals. CytC was found negatively correlated with ATP and PDH levels in HPT. GLP1Ra decreased the levels of CytC and SOD and increased PDH levels in CTR only after oral galactose.Conclusion: GLP1Ra might inhibit decreased PDH levels caused by single galactose load. GLP1R central inhibition has more pronounced effect in STZ‐icv treated rats suggesting the involvement of GLP1 signaling in model pathogenesis. Supported by Croatian Science Foundation and co‐financed by the Scientific Centre of Excellence for Basic, Clinical and Translational Neuroscience (project “Experimental and clinical research of hypoxic‐ischemic damage in perinatal and adult brain”; GA KK01.1.1.01.0007 funded by the European Union through the European Regional Development Fund).
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Open AccessThe involvement of GLP1 signaling with the effect of oral galactose in the hypothalamus of sporadic Alzheimer’s disease rat model
Background: Intracerebroventricular (icv) application of streptozotocin (STZ) causes mytochondrial dysfunction, oxidative stress and other metabolic effects, which leads to accumulation of τ‐protein and Aß plaques that makes it suitable for animal model of sporadic Alzheimer’s disease (sAD). We aimed to explore whether acute effect of single oral galactose dose is mediated by glucagon‐like peptide‐1 (GLP‐1) in sAD rat model.Method: Wistar rats were injected icv with STZ (3 mg/kg) or vehicle only (CTR). One month after the injection, animals were divided into three experiments. First experiment: 200 mg/kg galactose was given orally and CTR animals were sacrificed 30, 60 and 120 min after administration. Second experiment: GLP‐1R antagonist (Exendin 9‐39, 85 µg/kg; GLP1Ra) was administered icv in both groups and animals were sacrificed 30 min after the injection. Third experiment: 30 min prior to oral galactose, rats were injected icv with GLP‐1Ra, and animals were sacrificed 120 min after galactose load. PDH, COXIV, CytC and Casp‐3 levels were measured by Western blot method and lactate, ATP and SOD were measured by ELISA in HPT. Glucose, galactose and GLP‐1 levels were measured in plasma and CSF. Data were analyzed by principal component analysis and Spearman rank correlation.Result: Metabolic changes were found more pronounced 120 min after single galactose load: reduced levels of Casp‐3 and PDH and increased SOD levels in HPT; increased CSF glucose. GLP1Ra decreased the levels of lactate, COXIV and CytC and increased PDH and Casp‐3 levels in HPT, only in STZ treated animals. CytC was found negatively correlated with ATP and PDH levels in HPT. GLP1Ra decreased the levels of CytC and SOD and increased PDH levels in CTR only after oral galactose.Conclusion: GLP1Ra might inhibit decreased PDH levels caused by single galactose load. GLP1R central inhibition has more pronounced effect in STZ‐icv treated rats suggesting the involvement of GLP1 signaling in model pathogenesis. Supported by Croatian Science Foundation and co‐financed by the Scientific Centre of Excellence for Basic, Clinical and Translational Neuroscience (project “Experimental and clinical research of hypoxic‐ischemic damage in perinatal and adult brain”; GA KK01.1.1.01.0007 funded by the European Union through the European Regional Development Fund).
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
The effect of oral galactose on oxidative stress in the brain of a transgenic mice model of Alzheimer’s disease
Background: Changes in the brain energy metabolism and oxidative stress can be found before development of Aβ plaques in Alzheimer’s disease (AD) and galactose showed potential therapeutic effect in Tg2576 mice AD model. We aimed to investigate changes in the hippocampal (HPC) energy status and oxidative stress before and after galactose treatment in this model.Method: Adult male B6; SJL‐Tg(APPSWE)2576Kha transgenic (TG) mice (Tg2576) and wild types (WT) aged 5 (5M) and 10 (10M) months were used. Oral galactose therapy was given to half of WT (WT+G) and half of TG (TG+G) group for 2 months (200mg/kg/day), while another half of each group received water ad libitum. Protein expression of insulin receptor substrate (total and phosphorylated; IRS, pIRS), AMP‐activated protein kinase (AMPK, p‐AMPK) was measured by western blot. Corticosterone levels were measured by ELISA, and spectrophotometry were used to measure the parameters of oxidative stress (MnSOD; TBARS). Data were analyzed by Kruskal‐Wallis and Mann‐Whitney U‐test (pSupported by HRZZ IP‐2018‐01‐8938 and the Scientific Centre of Excellence for Basic, Clinical and Translational Neuroscience (project “Experimental and clinical research of hypoxic‐ischemic damage in perinatal and adult brain”, GA KK01.1.1.01.0007 funded by the European Union)
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Open AccessThe effect of oral galactose on oxidative stress in the brain of a transgenic mice model of Alzheimer’s disease
Background: Changes in the brain energy metabolism and oxidative stress can be found before development of Aβ plaques in Alzheimer’s disease (AD) and galactose showed potential therapeutic effect in Tg2576 mice AD model. We aimed to investigate changes in the hippocampal (HPC) energy status and oxidative stress before and after galactose treatment in this model.Method: Adult male B6; SJL‐Tg(APPSWE)2576Kha transgenic (TG) mice (Tg2576) and wild types (WT) aged 5 (5M) and 10 (10M) months were used. Oral galactose therapy was given to half of WT (WT+G) and half of TG (TG+G) group for 2 months (200mg/kg/day), while another half of each group received water ad libitum. Protein expression of insulin receptor substrate (total and phosphorylated; IRS, pIRS), AMP‐activated protein kinase (AMPK, p‐AMPK) was measured by western blot. Corticosterone levels were measured by ELISA, and spectrophotometry were used to measure the parameters of oxidative stress (MnSOD; TBARS). Data were analyzed by Kruskal‐Wallis and Mann‐Whitney U‐test (pSupported by HRZZ IP‐2018‐01‐8938 and the Scientific Centre of Excellence for Basic, Clinical and Translational Neuroscience (project “Experimental and clinical research of hypoxic‐ischemic damage in perinatal and adult brain”, GA KK01.1.1.01.0007 funded by the European Union)
- Open Access
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S426
GASTROINTESTINAL DYSHOMEOSTASIS IN A RAT MODEL OF SPORADIC ALZHEIMER’S DISEASE IS ASSOCIATED WITH DEFICIENT MUCUS SECRETION
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S426
Open AccessGASTROINTESTINAL DYSHOMEOSTASIS IN A RAT MODEL OF SPORADIC ALZHEIMER’S DISEASE IS ASSOCIATED WITH DEFICIENT MUCUS SECRETION
- Open Access
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S363
ASSOCIATION OF BEHAVIOURAL AND COGNITIVE TRAITS WITH GASTROINTESTINAL REDOX HOMEOSTASIS IN SYMPTOMATIC MIDDLE-AGED TG2576 MICE
- 5 November 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 15, S363
Open AccessASSOCIATION OF BEHAVIOURAL AND COGNITIVE TRAITS WITH GASTROINTESTINAL REDOX HOMEOSTASIS IN SYMPTOMATIC MIDDLE-AGED TG2576 MICE